ABSTRACT
Background Undiagnosed atrial fibrillation (AF) may cause preventable strokes. Guidelines differ regarding AF screening recommendations. We tested whether point-of-care screening with a handheld single lead electrocardiogram (ECG) at primary care practice visits increases diagnoses of AF.
Methods We randomized 16 primary care clinics 1:1 to AF screening using a handheld single-lead ECG (AliveCor KardiaMobile) during vital sign assessments, or usual care. Patients included were aged ≥ 65 years. Screening results were provided to primary care clinicians at the encounter. All confirmatory diagnostic testing and treatment decisions were made by the primary care clinician. New AF diagnoses over one-year follow-up were ascertained electronically and manually adjudicated. Proportions and incidence rates were calculated. Effect heterogeneity was assessed.
Results Of 30,715 patients without prevalent AF (n=15,393 screening [91% screened], n=15,322 control), 1.72% of individuals in the screening group had new AF diagnosed at one year versus 1.59% in the control group (risk difference [RD] 0.13%, 95% confidence interval [CI] −0.16–0.42, P=0.38). New AF diagnoses in the screening and control groups differed by age with the greatest effect observed for those aged ≥ 85 years (5.56% versus 3.76%, respectively, RD 1.80%, 95% CI 0.18–3.30). The difference in newly diagnosed AF between the screening period and the prior year was marginally greater in the screening versus control group (0.32% versus −0.12%, RD 0.43%, 95% CI −0.01–0.84). The proportion of individuals with newly diagnosed AF who were initiated on oral anticoagulants was similar in the screening (n=194, 73.5%) and control (n=172, 70.8%) arms (RD 2.7%, 95% CI −5.5–10.4).
Conclusions Screening for AF using a single-lead ECG at primary care visits was not associated with a significant increase in new AF diagnoses among individuals aged 65 years or older compared to usual care. However, screening may be associated with an increased likelihood of diagnosing AF among individuals aged 85 years or older and warrants further evaluation.
This study is registered with ClinicalTrials.gov, NCT03515057
Funding Bristol Myers Squibb-Pfizer Alliance
Competing Interest Statement
SAL is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. SAL receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, Fitbit, and IBM, and has consulted for Bristol Myers Squibb / Pfizer, Bayer AG, and Blackstone Life Sciences. SJA is supported by an American Heart Association grant (18SFRN34250007). SJA receives sponsored research support from Bristol Myers Squibb / Pfizer and has consulted for Bristol Myers Squibb/Pfizer and Fitbit. DES was supported by the Eliot B. and Edith C. Shoolman fund of the Massachusetts General Hospital (Boston, MA). He receives sponsored research funding from Bristol Myers Squibb / Pfizer and has consulted for Boehringer Ingelheim, Bristol Myers Squibb, Fitbit, Johnson and Johnson, Merck, and Pfizer. SK is supported by NIH grant T32HL007208. JMA is supported by NIH grant K01HL148506, American Heart Association 18SFRN34250007, and has received sponsored research support from Bristol Myers Squibb / Pfizer. DDM is supported by NIH grants R01HL137734 R01HL137794 R01HL141434 R01HL136660 R21AG060529 U54HL143541 U01HL146382 and receives sponsored research support from Apple, Bristol Myers Squibb / Pfizer, Boehringer Ingelheim, Flexcon, and has consulted for Bristol Myers Squibb / Pfizer, Heart Rhythm Society, Flexcon, and Avandia (Boston Biomedical) Associates.
Clinical Trial
NCT03515057
Funding Statement
The study was investigator-initiated and funded by the Bristol Myers Squibb-Pfizer Alliance.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocol was approved by the Mass General Brigham Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual participant data will not be made available owing to the sensitive and confidential nature of the personal health information contained. Additional reasonable requests for study documentation may be made to the corresponding author.
